HAEのチャート
HAEの企業情報
| symbol | HAE |
|---|---|
| 会社名 | Haemonetics Corp. （HAE ヘモネティクス） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ヘモネティクス(Haemonetics Corporation)はヘルスケア会社である。同社は顧客向けに血液加工・取扱・分析に従事する。同社のセグメントには日本、EMEA、北米プラズマと他を含む。同社は、血漿分画装置が医薬品を製造することを可能にする血漿収集システムおよびソフトウェアを提供する。同社は血漿採取顧客が「PCS」というブランドの血漿採取器具および使い捨て器具、血漿採取容器および生理食塩水を含む血漿採取・保存に必要な製品の供給源を得ることを可能にする。同社は自動化血液成分および手動全血採取システムを採血センターに提供し、血液製剤を収集する。同社は血液管理ソリューションを提供する。同社には血液駆動計画と血液採取のためのソリューションを含む統合ソフトウェアソリューションがある。 ヘモネティクスは、米国のヘルスケア企業。血漿から血液採取装置、医療機関まで血液サプライチェ―ンの各段階に合わせた血液管理ソリュ―ションの他、集積デバイス、情報管理、およびコンサルティングサ―ビスを提供する。同社の製品は、血漿、血液センタ―、病院、ソフトウェアソリュ―ションに分かれる。 Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following business segments: Plasma, Blood Center and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. The Hospital segment provides heomostasis management, cell salvage and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA. |
| 本社所在地 | 781 848-7100 |
| 代表者氏名 | Christopher Simon |
| 代表者役職名 | President Chief Executive Officer Director |
| 電話番号 | +1 781-848-7100 |
| 設立年月日 | 1971年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 3136人 |
| url | www.haemonetics.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 209.40200 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 4462.11800 |
| 売上高 | 売上高（百万ドル） 951.83600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4651.06400 |
| 当期純利益 | 当期純利益（百万ドル） 45.76400 |
| 決算概要 | 決算概要 BRIEF: For the 39 weeks ended 29 December 2018 Haemonetics Corporation revenues increased 7% to $718.3M. Net income before extraordinary items decreased 45% to $34.2M. Revenues reflect North America Plasma segment increase of 19% to $295.4M All other segment increase of 4% to $250.6M Japan segment increase of 3% to $52.2M United States segment increase of 10% to $452.5M Asia segment increase of 4% to $89.1M Japan segment increase of 6% to $52.3M. |
HAEのテクニカル分析
HAEのニュース
Haemonetics To Present At The 18th Annual Morgan Stanley Global Healthcare Conference 2020/09/09 20:53:00 PR Newswire
BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, Sept. 15, 2020, at 9:30 a.m. ET. The public may access Mr. Simon's…
Haemonetics First Quarter Fiscal 2021 Earnings Release Available on Investor Relations Website 2020/08/04 10:00:00 PR Newswire
BOSTON, Aug. 4, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal 2021, which ended June 27, 2020, are available on its Investor Relations website. In addition, the Company is also posting the earnings release and results…
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings 2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
M1 Kliniken: Sprung in neue Dimensionen 2020/06/25 19:00:00 BORSE ONLINE
Durch das Einbringen von Haemato wächst der Umsatz beim Schönheitskonzern M1 Kliniken um ein Vielfaches. Von Georg Pröbstl, Euro am Sonntag
High school staff make visors for new cancer hospital | On The Spot (OTS) News Southport 2020/06/22 16:16:16 OTS NEWS.co.uk
Face visors designed and made in a local high school are being donated for use in Liverpool’s first dedicated cancer hospital. The face visors, designed to be worn as PPE (personal protective equipment) against the spread of COVID-19 (coronavirus) and other infectious diseases, have been donated to frontline NHS workers in the new haemato-oncology ward at […]
Haemonetics To Present At The 18th Annual Morgan Stanley Global Healthcare Conference 2020/09/09 20:53:00 PR Newswire
BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, Sept. 15, 2020, at 9:30 a.m. ET. The public may access Mr. Simon's…
Haemonetics First Quarter Fiscal 2021 Earnings Release Available on Investor Relations Website 2020/08/04 10:00:00 PR Newswire
BOSTON, Aug. 4, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal 2021, which ended June 27, 2020, are available on its Investor Relations website. In addition, the Company is also posting the earnings release and results…
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings 2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
M1 Kliniken: Sprung in neue Dimensionen 2020/06/25 19:00:00 BORSE ONLINE
Durch das Einbringen von Haemato wächst der Umsatz beim Schönheitskonzern M1 Kliniken um ein Vielfaches. Von Georg Pröbstl, Euro am Sonntag
High school staff make visors for new cancer hospital | On The Spot (OTS) News Southport 2020/06/22 16:16:16 OTS NEWS.co.uk
Face visors designed and made in a local high school are being donated for use in Liverpool’s first dedicated cancer hospital. The face visors, designed to be worn as PPE (personal protective equipment) against the spread of COVID-19 (coronavirus) and other infectious diseases, have been donated to frontline NHS workers in the new haemato-oncology ward at […]